ReviewTranslational lung cancer research2015
Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity.
Review in Translational lung cancer research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Pooled it
- Efficacy and safety of combined immunotherapy and antiangiogenesis with or without chemotherapy for advanced non-small-cell lung cancer: A systematic review and pooled analysis from 23 prospective studies.Frontiers in pharmacology · 2022Pooled it
- Tumor immune microenvironment reconstitution in patient-derived organoids enables therapy modeling for NSCLC.Cell reports methods · 2026Article
- Article
- A novel mitochondria-related algorithm for predicting the survival outcomes and drug sensitivity of patients with lung adenocarcinoma.Frontiers in molecular biosciences · 2024Article
- Adjuvant immunotherapy in early-stage resectable non-small cell lung cancer: A new milestone.Frontiers in oncology · 2023Review
- [Research Progress of Immunotherapy for Non-small Cell Lung Cancer with Drive Gene Mutation].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2022Review
- Current and future drug combination strategies based on programmed death-1/programmed death-ligand 1 inhibitors in non-small cell lung cancer.Chinese medical journal · 2021Review
- Immuno-PET imaging ofCancer immunology, immunotherapy : CII · 2021Article
- Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib.Scientific reports · 2020Article
- The Effect and Safety of Anti-PD-1 Single/Combination Therapy in Refractory Thymic Carcinoma: A Case-Series Study.Cancer management and research · 2020Article
- Immune checkpoint inhibitors of PD-L1 as cancer therapeutics.Journal of hematology & oncology · 2019Review
- Article
- When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?Current treatment options in oncology · 2019Review
- Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer.Cancer management and research · 2019Article
- Advance of theragnosis biomarkers in lung cancer: from clinical to molecular pathology and biology.Journal of thoracic disease · 2019Review
- Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment.OncoTargets and therapy · 2018Review
- Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC).Therapeutic advances in medical oncology · 2018Review
- Integrated analysis of differential expression and alternative splicing of non-small cell lung cancer based on RNA sequencing.Oncology letters · 2017Article
- Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges.Immunotherapy · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The results of randomized clinical trials employing immune checkpoint inhibitors for pre-treated advanced non-small-cell lung cancer (NSCLC) have recently revolutionised the standard available option for this disease setting. Nevertheless, the validation of reliable predictive biomarkers, able to define that proportion of patients most likely to benefit from immunotherapy, represents a crucial and still unsolved issue. This intensive research aimed at selecting potentially predictive biomarkers for immunotherapy is developed together with a wide range of analyses investigating the molecular profiling of lung cancer, leading to the spontaneous question of how these two parallel aspects of the same disease may coexist and influence one another. The potential impact of the mutational landscape of lung cancer on tumor immunogenicity (in both oncogene-addicted and molecularly unselected disease) will be explored and discussed in this review in order to begin to answer the unsolved questions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.